Falcon Point Capital’s Pacira BioSciences PCRX Stock Holding History

Falcon Point Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-2,960	Closed	-$263K	–	122
2015 Q1	$263K	Buy	+2,960	New	+$300K	0.2%	105

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Falcon Point Capital's PCRX Position: Q2 2015 in Review

Falcon Point Capital sold out of Pacira BioSciences (PCRX) in Q2 2015, closing a stake of 2,960 shares — an estimated $263K sold.

Falcon Point Capital first reported a position in PCRX in Q1 2015 and held it in 1 quarter. The position peaked at $263K in Q1 2015. 187 funds tracked by Wall St. Rank hold PCRX as of Q2 2015.

Falcon Point Capital reported no remaining Pacira BioSciences position as of Q2 2015 after selling out during the quarter.
Falcon Point Capital sold 2,960 Pacira BioSciences shares in Q2 2015, an estimated $263K.
Falcon Point Capital first reported a position in Pacira BioSciences in Q1 2015 and held it in 1 quarter.
Falcon Point Capital's Pacira BioSciences position peaked at $263K in Q1 2015.
187 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2015.

Based on Falcon Point Capital's 13F filing for Q2 2015, filed 3 Aug 2015.